ASCO 2018 | CAR T-cell combination therapies to improve response durability

Jeremy Abramson

CAR T-cell monotherapies have produced promising results; however, the duration of remission needs to be optimized. Here, Jeremy Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, highlights how combination regimens could improve response durability. He highlights the PLATFORM trial (NCT03310619), which is investigating CAR T-cell product lisocabtagene maraleucel combinations in relapsed/refractory B-cell malignancies. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.

Share this video